Refine by
Patient Follow Up Articles & Analysis
94 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida’s SB 1768, ...
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
The dose levels that are evaluated in the Phase 1 part of the study are 50x106 (DL1), 110x106 (DL2) and 250x106 (DL3). As of 8 November 2022, 9 patients were enrolled; baseline and safety data for 8 patients were available (n=4 at DL1; n=4 at DL2). 7 patients reached the follow-up period of 28-days and were ...
In addition, this web-based solution will incorporate Definition Health’s Total Digital Surgery platform which assists hospitals and surgeons in achieving workflow efficiency, improved perioperative care and virtual follow up for surgical patients. Definition Health’s platform is widely deployed in the UK with customers reporting ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 months and extend ...
“The analysis of the LungFit PRO study in VCAP patients further demonstrates improved efficacy on multiple parameters in the iNO treatment group compared to standard supportive treatment (SST). ...
“With the ISET technology, we were able to effectively extract CTC in higher numbers and from larger DLA volumes, in all cases thus increasing sensitivity for further studies of CTC in NSCLC patients,” said Dr. Menno Tamminga. Davide Brechot, Deputy Director and CTO of Rarecells Diagnostics commented: “Dr. ...
The results, with an average of six months follow up in patients that received three cycles of therapy in Cohorts 5 and 6, showed a statistically significant reduction in the tumor growth rate (-0.296 mm/yr, p = 0.0007) compared to each patient’s documented growth rate at study entry, and an 88.9% (8/9) tumor control rate. ...
For onset of visual symptoms, refer patients for ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYTGOBI. ...
” About the ReFlow® System Mini The ReFlow® System Mini is designed to help patients with CSF disorders, such as hydrocephalus, a debilitating and life-threatening condition affecting more than 30 million patients worldwide. ...
Relief can last anywhere from a few days up to a full year after treatment. This gives the patient time to recover from their injury by engaging in helpful rehab movements. ...
The study calls for treating 64 patients and includes a 6-month follow-up for each patient, as is typical. ...
ByImricor
Key findings from the completed 30 mg cohort of the SHORELINE Study, other clinical data and health economics and outcomes research (HEOR), and patient survey data being presented include: In an analysis of patients in the 30 mg cohort of the SHORELINE Study with elevated anxiety (n=569) and without elevated anxiety (n=156), there was a mean reduction in the ...
These three organizations working together will create trials that will impact hundreds, if not thousands of patients. “I am so honored and pleased to see our vision of cancer research come closer to trial and real-time treatment of patients. ...
The trial previously exceeded its target of 135 LimiFlex patients enrolled into the investigational arm and 160 patients enrolled into the control arm of the trial. ...
No identifiable prior medical treatment; Impossibility for the patient to participate in prolonged medical follow-up; Unstable psychotic disorders, severe depressive syndromes that have not been stabilized with a specific treatment, suicidal tendencies; Alcoholism or drug addiction; Severe eating disorders (such as bulimia); An insufficient ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the ...
Our goal is to reproduce the Phase IIb clinical trial results, which showed no metastatic breast cancer recurrences in patients treated with GLSI-100 over 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 ...